Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 293-301

  Kailasam, Chandra ^a   Cahill, David ^b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Contraception; Intrauterine device; Levonorgestrel intrauterine device

Indexed keywords

EID: 84865469611     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S3464     Document Type: Review

References (74)

1. Abou-Setta AM, Al-Inany HG, Farquhar CM. 2006. Levonorgestrelreleasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database of Systematic Reviews, Issue 4.
2. Andersson K., Batar I, Rybo G. 1992. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception, 46:575-84.
3. Andersson K., Odlind V, Rybo G. 1994. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use. A randomized comparative trial. Contraception, 49:56-72.
4. Anderson J. K, Rybo G. 1990. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol, 97:690-4
5. Backman T., Huhtala S, Luoto R, et al. 2002. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol, 99:608-13.
6. Backman T., Rauramo I, Huhtala S, et al. 2004. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol, 190:50-4.
7. Backman T., Rauramo I, Jaakkola K, et al. 2005. Use of the levonorgestrelreleasing intrauterine system and breast cancer. Obstet Gynecol, 106:813-7.
8. Bahamondes L., Espejo-Arce X, Hidalgo MM, et al. 2006. A cross-sectional study of the forearm bone density of long-term users of levonorgestrelreleasing intrauterine system. Hum Reprod, 21:1316-9.
9. Blumenthal P. D, Trussell J, Singh RH, et al. 2006. Cost-effectiveness of treatments for dysfunctional uterine bleeding in women who need contraception. Contraception, 74:249-58.
10. Bonacho I., Pita S, Gomez-Besteiro MI. 2001. The importance of the removal of the intrauterine device in genital colonization by actinomyces. Gynecol Obstet Invest, 52:119-23.
11. Braghetoa A. M, Casertab N, Bahamondes L, et al. 2007. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception, 76:195-9.
12. Budiman H., Kümper C, Mylonas I, et al. 2007. Pregnancy in a patient with a displaced levonorgestrel-releasing intrauterine system: a case report. Arch Gynecol Obstet, 276:263-4.
13. Chan S., Tam W, Yeo W, et al. 2007. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG, 114:1510-5.
14. Clegg J. P, Guest JF, Hurskainen R. 2007. Cost-utility of levonorgestrel intrauterine system compared with hysterectomy and second generation endometrial ablative techniques in managing patients with menorrhagia in the UK. Curr Med Res Opin, 23:1637-48.
15. Cho S. H, Nam A, Kim HY, et al. 2008. Clinical effects of the levonorgestrelreleasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol, 198:373. e1-7.
16. Chrisman C., Ribeiro P, Dalton VK. 2007. The levonorgestrel-releasing intrauterine system: an updated review of the contraceptive and noncontraceptive uses. Clin Obstet Gynecol, 50:886-97.
17. d'Arcangues C. 2006. WHO statement on hormonal contraception and bone health. Contraception, 73:443-4.
18. El Tagy A, Sakr E, Sokal DC, et al. 2003. Safety and acceptability of postabortal IUD insertion and the importance of counselling. Contraception, 67:229-34.
19. ESHRE Capri Workshop Group. 2008. Intrauterine devices and intrauterine systems. Hum Reprod Update, 14:197-208.
20. Farley T. MM, Rowe PJ, Meirik O, et al. 1992. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet, 339:785-8.
21. Forrest A., Amarakone I, Lord J. 2008. Retained hormone release capsule following removal of Mirena intrauterine system. BJOG, 115:130-1.
22. French R., Van Vliet H, Cowan F, et al. 2004. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database of Systematic Reviews, Issue 3. Art. No: CD001776.
23. [FSRH] Faculty of Sexual and Reproductive Healthcare Guidance. Clinical Effectiveness Unit. 2007. Intrauterine Contraception.
24. Gardner F. J, Konje JC, Abrams KR, et al. 2000. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet, 356:1711-7.
25. Grimes D.A. 2000. Intrauterine device and upper-genital-tract infection. Lancet, 356:1013-109.
26. Grimes D. A, Lopez LM, Manion C, et al. 2007. Cochrane systematic reviews of IUD trials: lessons learned. Contraception, 75:S55-S9.
27. Grimes D., Mishell Jr D. 2008. Intrauterine contraception as an alternative to interval tubal sterilization. Contraception, 77:6-9.
28. Grimes D. A, Schulz KF. 2001. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev, CD001327.
29. Guttinger A., Critchley HO. 2007. Endometrial effects of intrauterine levonorgestrel. Contraception, 75:S93-S8.
30. Haimov-Kochman R, Amsalem H, Adoni A, et al. 2003. Management of a perforated levonorgestrel-medicated intrauterine device-a pharmacokinetic study: case report. Hum Reprod, 18:1231-3.
31. Hurskainen R., Teperi J, Rissanen P. 2004. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA, 291:1456-63
32. Inki P. 2007. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception, 75(6 Suppl):S161-6.
33. Inki P., Hurskainen R, Palo P, et al. 2002. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol, 20:381-5.
34. Istre O., Qvigstad E. 2007. Current treatment options for abnormal uterine bleeding: an evidence-based approach. Best Pract Res Clin Obstet Gynaecol, 21:6:905-13.
35. Jensen J. T, Nelson AL, Antonio C. 2008. Subject and clinician experience with the levonorgestrel-releasing intrauterine system Contraception, 77:22-9.
36. Jonsson B., Landgren B-M, Eneroth P. 1991. Effects of various IUDs on the composition of cervical mucus. Contraception, 43:447-58.
37. Kresowik J., Ryan GL, Van Voorhis BJ. 2008. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol, 111:547-9.
38. Kadir R. A, Chi C. 2007. Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy. Contraception, 75:S123-S9.
39. Kaunitz A.M. 2007. Progestin-releasing intrauterine systems and leiomyoma. Contraception, 75:S130-S3.
40. Lähteenmäki P., Rauramo I, Backman T. 2000. The levonorgestrel intrauterine system in contraception. Steroids, 65:693-7.
41. Lethaby A. E, Cooke I, Rees M. 2005. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews, Issue 4. Art. No: CD002126
42. Lockhat F. B, Emembolu JE, Konje JC. 2005. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil Steril, 83:398-404.
43. Luukkainen T., Lahteenmaki P, Toivonen J. 1990. Levonorgestrel-releasing intrauterine device. Ann Med, 22:85-90.
44. Marjoribanks J., Lethaby A, Farquhar C. 2006. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev, 19(2):CD003855.
45. Mohllajee A. P, Curtis KM, Peterson HB. 2006. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception, 73:145-53.
46. [NICE] National Institute for Health and Clinical Excellence Guidelines. 2005. Long acting reversible contraception.
47. Nilsson C. G, Lahteenmaki P, Luukkainen T. 1980. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception, 21:225-33.
48. Odlind V. 1996. Modern intrauterine devices. Baillieres Clin Obstet Gynaecol, 10:55-67.
49. Pakarinen P., Toivonen J, Luukkainen T. 2003. Randomized comparison of levonorgestrel-and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception, 68:31-4.
50. Petta C. A, Ferriani RA, Abrão MS, et al. 2005. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod, 20:1993-8.
51. Pisoni C. N, Cuadrado MJ, Khamashta MA, et al. 2005. Treatment of menorrhagia associated with oral anticoagulation: efficacy of levonorgestrel releasing intrauterine device. Thromb Res, 115(Suppl 1):121-2.
52. Prager S., Darney PD. 2007. The levonorgestrel intrauterine system in nulliparous women. Contraception, 75(6 Suppl):S12-5.
53. Progress in Reproductive Health Research, Issue 60, WHO 2002.
54. Riphagen F.E. 2000. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric, 3:199-211.
55. Rönnerdag M., Odlind V. 1999. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand, 78:716-21.
56. Shaamash A. H, Sayed G, Hussien M, et al. 2005. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception, 72:346-51.
57. Sitruk-Ware R. 2007. The levonorgestrel intrauterine system for use in periand postmenopausal women. Contraception, 75:S155-S60.
58. Sivin I., Stern J, Coutinho E, et al. 1991. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception, 44:473-80.
59. Soysal S., Soysal ME. 2005. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest, 59:29-35.
60. Suhonen S., Haukkamaa M, Jakobsson T, et al. 2004. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception, 69:407-12.
61. Thonneau P. F, Almont TE. 2008. Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol, 198:248-53.
62. Toivonen J., Luukkainen T, Allonen H. 1991. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel-and copper-releasing intrauterine devices. Obstet Gynecol, 77:261-4.
63. Trinh X. B, Tjalma WA, Makar AP, et al. 2008. Use of the levonorgestrelreleasing intrauterine system in breast cancer patients. Fertil Steril, 90:17-22.
64. Varma R., Sinha D, Gupta JK. 2006. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)-a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol, 125:9-28.
65. Varma R., Soneja H, Bhatia K, et al. 2008. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-A long-term follow-up study. Eur J Obstet Gynecol Reprod Biol, Apr 25 [Epub ahead of print].
66. Van Houdenhoven K, van Kaam KJAF, van Grootheest AC, et al. 2006. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception, 73:257-60.
67. Vercellini P., Frontino G, De Giorgi O, et al. 2003. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril, 80:305-9.
68. WHO. 2004. Medical eligibility criteria for contraceptive use. World Health Organization. URL: http://www.who.int/reproductive-health/ publications/mec/7_iud.pdf
69. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), INFO Project. 2007. Family Planning: A Global Handbook for Providers. Baltimore and Geneva: CCP and WHO.
70. Wildemeersch D. 2007. New frameless and framed intrauterine devices and systems-an overview. Contraception, 75(6 Suppl):S82-92.
71. Wildemeersch D., Janssens D, Pylyser K, et al. 2007b. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas, 57: 210-3.
72. Wildemeersch D., Pylyser K, Wever N, et al. 2007a. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas, 57:205-9.
73. Zalel Y., Gamzu R, Shulman A, et al. 2003. The progestative effect of the levonorgestrel-releasing intrauterine system-when does it manifest? Contraception, 67:473-6.
74. Xiao B., Wu SC, Chong J, et al. 2003. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril, 79:963-9.